Impax to pay $35 million to settle part of Solodyn antitrust litigation

Impax to pay $35 million to settle part of Solodyn antitrust litigation


Impax Laboratories Inc has agreed to pay $35 million to resolve part of litigation over claims it entered into an anticompetitive deal in a patent case to delay releasing a generic version of the acne medication Solodyn. The settlement was disclosed in papers filed in federal court in Boston on Saturday.



from Biotech News